Harlan Robins, Ph.D., is a co-founder and head of innovation at Adaptive Biotechnologies headquartered in Seattle. He is also the Computational Biology Program Head at the Fred Hutchinson Cancer Research Center (FHCRC). Robins has a bachelor’s degree in physics from Harvard, and a master’s degree and Ph.D. in theoretical string theory physics from the University of California Berkeley. He completed postdoctoral work at Weizmann Institute of Science in Israel and the Institute for Advanced Study at Princeton in New Jersey. At Princeton, Robins worked with biologist Arnold Levine developing bioinformatic algorithms for microRNA targets and bacterial genome analysis.
Robins focuses on the quantitative analysis of the adaptive immune system. His approach takes advantage of new high-throughput sequencing technology he developed with his collaborators. His group is isolating and sequencing millions of adaptive immune receptor rearrangements to profile the adaptive immune system. With this new technology, he is working toward a comprehensive description of the T-cell repertoire and studying the dynamics of immune response. He is applying this technology in multiple clinical settings including hematopoietic stem cell transplants (HSCT) and cancer immunotherapy.